Revance Therapeutics (NASDAQ:RVNC) has been assigned a $40.00 target price by research analysts at Barclays in a report issued on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Barclays’ price target indicates a potential upside of 13.48% from the stock’s current price.

A number of other analysts have also issued reports on RVNC. Cantor Fitzgerald set a $50.00 target price on shares of Revance Therapeutics and gave the company a “buy” rating in a research note on Wednesday, December 13th. JMP Securities began coverage on shares of Revance Therapeutics in a research note on Tuesday, August 22nd. They set an “outperform” rating and a $34.00 target price for the company. SunTrust Banks boosted their target price on shares of Revance Therapeutics to $53.00 and gave the company a “buy” rating in a research note on Friday, December 8th. Zacks Investment Research raised shares of Revance Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a research note on Wednesday, August 30th. Finally, Mizuho lifted their price objective on Revance Therapeutics from $37.00 to $54.00 and gave the company a “buy” rating in a report on Wednesday, December 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $43.11.

Shares of Revance Therapeutics (RVNC) opened at $35.25 on Tuesday. Revance Therapeutics has a one year low of $18.00 and a one year high of $37.20.

Revance Therapeutics (NASDAQ:RVNC) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.95) by ($0.06). The company had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.05 million. Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.64) earnings per share. analysts expect that Revance Therapeutics will post -3.73 earnings per share for the current year.

In other news, Director Mark J. Foley bought 20,000 shares of Revance Therapeutics stock in a transaction on Tuesday, November 7th. The stock was acquired at an average cost of $26.96 per share, for a total transaction of $539,200.00. Following the completion of the acquisition, the director now owns 6,000 shares of the company’s stock, valued at approximately $161,760. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO L Daniel Browne sold 7,600 shares of the business’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $24.94, for a total transaction of $189,544.00. Following the completion of the transaction, the chief executive officer now owns 133,188 shares of the company’s stock, valued at $3,321,708.72. The disclosure for this sale can be found here. Insiders sold 36,426 shares of company stock valued at $956,026 over the last 90 days. 18.86% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its holdings in Revance Therapeutics by 4.8% in the second quarter. JPMorgan Chase & Co. now owns 3,626,603 shares of the biopharmaceutical company’s stock worth $95,743,000 after purchasing an additional 166,759 shares in the last quarter. Franklin Resources Inc. raised its holdings in Revance Therapeutics by 13.1% in the second quarter. Franklin Resources Inc. now owns 3,375,238 shares of the biopharmaceutical company’s stock worth $89,106,000 after purchasing an additional 391,638 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Revance Therapeutics by 14.4% in the second quarter. Bank of New York Mellon Corp now owns 2,079,562 shares of the biopharmaceutical company’s stock worth $54,901,000 after purchasing an additional 261,764 shares in the last quarter. Vanguard Group Inc. raised its holdings in Revance Therapeutics by 7.3% in the second quarter. Vanguard Group Inc. now owns 931,623 shares of the biopharmaceutical company’s stock worth $24,595,000 after purchasing an additional 63,505 shares in the last quarter. Finally, State Street Corp raised its holdings in Revance Therapeutics by 0.6% in the second quarter. State Street Corp now owns 452,490 shares of the biopharmaceutical company’s stock worth $11,944,000 after purchasing an additional 2,637 shares in the last quarter. Institutional investors and hedge funds own 76.69% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Revance Therapeutics (RVNC) PT Set at $40.00 by Barclays” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/revance-therapeutics-rvnc-pt-set-at-40-00-by-barclays/1775850.html.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.